A Legacy of Dedication: The Fishbone Family’s Enduring Impact on Type 1 Diabetes Research

Marilyn and Dr. Gerald Fishbone were not merely supporters of type 1 diabetes (T1D) research; they were architects of progress, their lives interwoven with the very fabric of the T1D community for over five decades. Their profound dedication, ignited by a personal diagnosis within their family, evolved into a multi-generational commitment to advancing innovative research, a legacy that continues to inspire and drive change. Dr. Gerald Fishbone passed away on January 16, 2023, and his beloved wife, Marilyn, followed him on March 31, 2026, leaving behind an indelible mark on the landscape of T1D advocacy and scientific advancement.

The Genesis of a Lifelong Commitment

The Fishbone family’s deep engagement with the T1D cause began in 1969, a pivotal year marked by the diagnosis of their then 18-month-old son, Scott, with type 1 diabetes. At a time when awareness and understanding of the condition were significantly less widespread, Marilyn recalled in a 2021 interview with Breakthrough T1D (formerly known as the Juvenile Diabetes Research Foundation, or JDRF, and now Breakthrough T1D), "I had never heard of diabetes. No one in our family, before Scott, had diabetes." This profound personal encounter with the challenges of T1D immediately propelled the Fishbones into action, transforming their shock into a powerful impetus for change.

Their initial involvement was with what was then the Juvenile Diabetes Research Foundation (JDRF). This nascent partnership quickly blossomed into a lifelong commitment. Marilyn, driven by her newfound understanding and a fierce desire to support other families, went on to found the New Haven, Connecticut, Chapter of the organization. Her role as an engaged volunteer and a consistent donor underscored her unwavering commitment to the cause.

Dr. Gerald Fishbone, a distinguished figure in his own right, also channeled his expertise and passion into Breakthrough T1D. His contributions spanned a remarkable array of leadership roles. He served as Chair of the Breakthrough T1D International Board of Directors (IBOD), providing strategic direction and global oversight. His medical acumen was invaluable as a Medical Advisor, and he actively participated in the Research Committee, directly influencing the allocation of vital research funding. Beyond his active roles, both Gerald and Marilyn were consistent and generous donors, understanding that financial support was crucial for sustaining the vital research they championed.

A Family United in Purpose: The Fishbone Legacy Continues

The Fishbones’ commitment was not confined to their individual efforts; it was a deeply ingrained family value, a passion they successfully transmitted to their children and grandchildren. This multi-generational dedication ensures that their legacy of service continues to thrive and expand.

Their daughter, Lisa Fishbone Wallack, has followed in her parents’ footsteps, assuming a prominent leadership position within the organization. In 2024, Lisa became Chair of the IBOD, a testament to her extensive experience and dedication. Prior to this, she served as Vice Chair of the IBOD and also held the position of President of the Greater New England Chapter, demonstrating a breadth of leadership across different organizational levels.

Their son, Scott, the catalyst for the family’s involvement, remains a dedicated volunteer leader within Breakthrough T1D. He actively contributes to the New Jersey Chapter Board and holds a significant role as Advocacy Co-chair on the Chapter’s Executive Committee. This positions him at the forefront of efforts to influence policy and raise public awareness, ensuring that the voice of the T1D community is heard.

Marilyn’s poignant reflection encapsulates the family’s holistic approach to their advocacy: "We believe in being involved and giving back," she stated. "Our kids joke that they never ate on a clean dining table because it was always covered in Breakthrough T1D fundraising envelopes. Most of the time, it was. We worked extremely hard and committed ourselves as a family to giving our time and energy to Breakthrough T1D and to inspiring others to join us." This vivid anecdote paints a picture of a household where T1D advocacy was not just an activity, but a way of life, deeply integrated into the daily routines and family dynamics.

A Turning Point: The Impact of Advancements

The Fishbone family’s journey with T1D research also provided them with a unique perspective on the transformative power of scientific progress. In 2001, their then 5-year-old grandson, Harris Wallack, was diagnosed with T1D. This second diagnosis within the family, occurring over three decades after Scott’s, offered a stark and hopeful comparison.

Marilyn elaborated on this profound difference: "His diagnosis, while still devastating, was so different. The technology available to make it safer and easier to manage T1D was drastically improved from when Scott was diagnosed," she explained. "That is all thanks to the strategic leadership of Breakthrough T1D." This observation highlights the tangible impact of the research and advocacy that the Fishbones had tirelessly supported. The advancements in continuous glucose monitors (CGMs), insulin pumps, and sophisticated management algorithms, all products of dedicated research and funding, had significantly improved the quality of life and safety for individuals living with T1D.

The Evolving Landscape of T1D Management and Research

Type 1 diabetes is a chronic autoimmune disease characterized by the pancreas’s inability to produce insulin, a hormone essential for regulating blood sugar. This leads to a buildup of glucose in the bloodstream, which can cause serious long-term complications affecting the heart, kidneys, eyes, and nerves. Historically, managing T1D involved frequent blood glucose testing with finger pricks, multiple daily insulin injections, and meticulous carbohydrate counting, a regimen that was often burdensome and carried a significant risk of both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar).

The period between Scott’s diagnosis in 1969 and Harris’s in 2001 witnessed a revolution in T1D care, largely driven by organizations like Breakthrough T1D. Early research focused on understanding the autoimmune basis of the disease, paving the way for the development of more sophisticated insulin therapies. The advent of rapid-acting insulins, followed by the development of the insulin pump, allowed for more flexible and precise insulin delivery. Perhaps the most significant leap forward during this era was the development of continuous glucose monitoring (CGM) technology. CGMs provide real-time glucose readings, allowing individuals and their caregivers to anticipate and prevent dangerous highs and lows. This technology, coupled with advanced insulin algorithms, has moved the T1D community closer to the concept of an artificial pancreas, where devices automatically adjust insulin delivery based on CGM data.

The Fishbones’ personal experiences directly mirror this trajectory. Scott’s early years likely involved the more challenging management protocols of the time, while Harris’s diagnosis benefited from the technological innovations that had emerged. This contrast underscores the direct correlation between sustained research investment and improved patient outcomes, a principle that the Fishbones deeply understood and championed.

Data-Driven Impact and Future Implications

The impact of Breakthrough T1D’s research funding, championed by families like the Fishbones, is quantifiable. Over the decades, the organization has invested billions of dollars in T1D research. This investment has yielded significant breakthroughs, including:

• Improved Diagnostics and Monitoring: As highlighted by Marilyn’s statement, the development and widespread adoption of CGMs have been a game-changer, reducing the burden of finger pricks and providing critical data for better management. The accuracy and accessibility of these devices have increased dramatically, with many individuals now relying on them as their primary glucose monitoring tool.
• Advanced Insulin Therapies: The development of insulin analogs with different pharmacokinetic profiles has allowed for more precise insulin dosing, mimicking the body’s natural insulin secretion more closely.
• Understanding Autoimmunity: Research has deepened our understanding of the autoimmune processes that cause T1D, opening avenues for potential immune-modulating therapies aimed at preventing or even reversing the disease.
• The Road to a Cure: While a cure for T1D remains the ultimate goal, significant progress is being made in areas such as islet cell transplantation, gene therapy, and immune tolerance, offering hope for a future free from the daily burden of insulin injections and blood sugar monitoring.

The Fishbones’ dedication, therefore, directly contributed to these advancements. Their consistent support enabled Breakthrough T1D to fund groundbreaking studies, attract top scientific talent, and translate laboratory discoveries into real-world solutions. The ongoing commitment from their children and grandchildren ensures that this vital funding stream and advocacy pipeline remain strong. The appointment of Lisa Fishbone Wallack as Chair of the IBOD signifies a continued strategic vision for the organization, likely focusing on accelerating research towards a cure and further improving the lives of those living with T1D. Scott’s advocacy work ensures that the patient perspective remains central to policy decisions and public awareness campaigns.

Acknowledging a Profound Loss

The passing of both Marilyn and Dr. Gerald Fishbone represents a profound loss to the T1D community. Their unwavering commitment, personal sacrifices, and the enduring legacy they have built through their family serve as a powerful reminder of the impact that dedicated individuals can have on advancing critical medical research and improving countless lives. Their story is not just one of personal tragedy transformed into advocacy, but a testament to the power of familial love, resilience, and the collective pursuit of a future where type 1 diabetes is no longer a life-altering diagnosis. The Fishbones are deeply missed, and their dedication and generosity to Breakthrough T1D will undoubtedly resonate within the T1D community for generations to come, a beacon of hope and a call to continued action. Their lives exemplify the profound difference that sustained commitment can make in the fight against chronic diseases.